Patients with CLL responding to initial chemotherapy with fludarabine alone (F) or in
combination with cyclophosphamide (FC) were randomized for treatment with alemtuzumab …

Alemtuzumab has shown considerable activity in untreated and relapsed chronic
lymphocytic leukaemia. We report our long‐term experience in 21 patients within a …

Purpose We conducted a randomized trial to evaluate the efficacy and safety of intravenous
alemtuzumab compared with chlorambucil in first-line treatment of chronic lymphocytic …

PURPOSE: This phase II pilot study determined the efficacy and safety of alemtuzumab
(Campath-1H; Burroughs Wellcome, United Kingdom) in patients with chronic lymphocytic …

Purpose The phase II CLL2H trial evaluated safety and efficacy of subcutaneous
alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL) …

Purpose Treatment with alemtuzumab has resulted in negative responses for minimal
residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL). In a prior …

Abstract The randomized Haemato Oncology Foundation for Adults in The Netherlands 68
phase 3 trial compared front-line chemotherapy with chemotherapy plus the CD52 …

Background Chronic lymphocytic leukaemia (CLL) is an incurable and chronic disorder, with
worsening prognosis for patients as their disease progresses. We compared the efficacy and …

Purpose To test whether eradication of minimal residual disease (MRD) in B-cell chronic
lymphocytic leukemia (CLL) by alemtuzumab is associated with a prolongation of treatment …

Purpose To determine if alemtuzumab consolidation improves response rate and
progression-free survival (PFS) after induction chemoimmunotherapy in previously …